Search Results
Your search for all items matches 264 pages
Showing 201 - 250FDA Approves Lenvatinib in Combination With Everolimus in Advanced Renal Cell Carcinoma
On May 13, 2016, the U.S. Food and Drug Administration (FDA) approved lenvatinib capsules (Lenvima), in combination with everolimus (Afinitor) for the treatment of advanced renal cell carcinoma following one prior antiangiogenic therapy. Lenvatinib was first approved in 2015 for the treatment...
FDA Approves Cabozantinib in Patients With Renal Cell Carcinoma Who Have Received Prior Antiangiogenic Therapy
On April 25, 2016, the U.S. Food and Drug Administration (FDA) approved cabozantinib (Cabometyx) tablets for the treatment of advanced renal cell carcinoma in patients who have received prior antiangiogenic therapy. Cabozantinib is a dual tyrosine kinase inhibitor of MET and VEGFR2. The...
Study Finds Apitolisib Less Effective Than Everolimus in Metastatic Renal Cell Carcinoma
As reported in the Journal of Clinical Oncology by Powles et al, the dual PI3K/mTOR inhibitor apitolisib was inferior to the mTOR inhibitor everolimus (Afinitor) in progression-free survival in a phase II trial in patients with metastatic clear cell renal cell carcinoma progressing on or after...
No Disease-Free Survival Benefit of Adjuvant Sunitinib or Sorafenib in High-Risk Nonmetastatic Renal Cell Carcinoma
In a phase III trial (ECOG-ACRIN E2805) reported in The Lancet by Haas et al, no benefit of adjuvant VEGFR (vascular endothelial growth factor receptor) inhibitor treatment with sunitinib or sorafenib (Nexavar) was observed vs placebo in patients with completely resected high-risk nonmetastatic...
Removal of Complex Renal Tumors Performed Safely by Robotic Surgery in Selected Patients
Renal cell carcinoma can sometimes spread to the inferior vena cava, posing a threat to the heart and brain. Robotic nephrectomy for inferior vena cava tumor thrombus has favorable outcomes in selected patients compared with open surgery, which can have a high rate of complications, reported Abaza...
Eric Jonasch, MD, on Kidney Cancer: Current and Novel Treatment Options
Eric Jonasch, MD, of The University of Texas, MD Anderson Cancer Center, discusses the progress being made in kidney cancer treatment and the clinical trials that focused on sunitinib, sorafenib, and everolimus, among others.
Cora N. Sternberg, MD, on New Targets in Renal Cell Carcinoma
Cora N. Sternberg, MD, of San Camillo Forlanini Hospital, summarizes a teaching lecture on new targets in renal cell carcinoma, and discusses what to expect for the future of treating RCC.
Brian I. Rini, MD, on A Cancer Vaccine for Renal Cell Carcinoma
Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses the results from a phase III study investigating a multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic renal cell carcinoma (Abstract 17LBA).
Robert J. Motzer, MD, on Phase III Results of CheckMate 025 Nivolumab vs Everolimus in Advanced RCC
Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, discusses the results of this study, which could well change the treatment paradigm in patients with previously treated metastatic renal cell carcinoma (Abstract 3LBA).
Toni K. Choueiri, MD, on Cabozantinib vs Everolimus in Patients With Advanced Renal Cell Carcinoma
Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses results of the phase III METEOR trial in advanced renal cell carcinoma, which evaluated the efficacy of cabozantinib compared to everolimus in patients with disease progression after VEGFR-targeted therapy (Abstract 4LBA).
Toni Choueiri, MD: Renal Cancer Update
Toni Choueiri, MD, of the Dana-Farber Cancer Institute, summarizes key points from a session he chaired on clear and non-clear cell renal cancer, including information on molecular genetics and its impact on treatment, how to treat patients with non-clear cell histology, and the best strategy for...
Hans-Joerg Hammers, MD, PhD, on Renal Cancer: Using Immune Checkpoint Blockers in the Clinic
Hans-Joerg Hammers, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, summarizes this keynote lecture on kidney cancer, which included discussion of the current role of PD-1 monotherapy and future PD-1 combination therapies for renal cell carcinoma.
Bernard J. Escudier, MD, on Renal Cell Carcinoma: Results From the METEOR Trial (French Language Version) 
Bernard J. Escudier, MD, of the Institut Gustave Roussy, discusses in French a subgroup analyses of this phase III study of cabozantinib vs everolimus in patients with advanced renal cell carcinoma (Abstract 499).
Bernard J. Escudier, MD, on Renal Cell Carcinoma: Results From the METEOR Trial
Bernard J. Escudier, MD, of the Institut Gustave Roussy, discusses a subgroup analyses of this phase III study of cabozantinib vs everolimus in patients with advanced renal cell carcinoma (Abstract 499). To see the French language version of this video, click here.
GU Symposium 2016: Cabozantinib Improves Upon the Standard of Care for Advanced Kidney Cancer
New analyses from a phase III clinical trial of patients with previously treated advanced kidney cancer demonstrated that patients of all risk levels experience more benefit from cabozantinib (Cometriq) than from the current standard of care, everolimus (Afinitor). The greater activity of...
Molecular Characterization of Papillary Renal Cell Carcinoma Shows Differences Between Type 1 and 2 Tumors
Comprehensive molecular characterization of primary papillary renal cell carcinoma, reported in The New England Journal of Medicine by The Cancer Genome Atlas Research Network, showed that type 1 and 2 papillary renal cell carcinomas were distinct types of disease based on differences in genetic...
FDA Approves Nivolumab to Treat Advanced Kidney Cancer
The U.S. Food and Drug Administration today approved nivolumab (Opdivo) to treat patients with metastatic renal cell carcinoma who have received a prior antiangiogenic therapy. Nivolumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2,...
Kidney Failure and Its Treatment May Impact Cancer Risk
For patients with kidney failure, poor kidney function and immunosuppressant medications may increase their risk of developing different types of cancer. The findings, which are published by Yanik et al in the Journal of the American Society of Nephrology, suggest the need for persistent cancer...
Increased Meat Consumption May Be Linked to Elevated Kidney Cancer Risk
Diets high in meat may lead to an increased risk of developing renal cell carcinoma through intake of carcinogenic compounds created by certain cooking techniques, such as barbecuing and pan-frying. As part of a new study from The University of Texas MD Anderson Cancer Center, published by...
Second-Line Lenvatinib Plus Everolimus Improves Progression-Free Survival vs Everolimus in Metastatic Renal Cell Carcinoma in Phase II Trial
In a phase II trial reported in The Lancet Oncology, Motzer et al found that the combination of the multi–tyrosine kinase inhibitor lenvatinib (Lenvima) plus the mTOR inhibitor everolimus (Afinitor) significantly improved progression-free survival vs everolimus alone in patients with...
Risk-Based Approach to Guide Surveillance After Resection for Renal Cell Carcinoma
As reported in the Journal of Clinical Oncology, Stewart-Merrill et al at Mayo Clinic, Rochester, have developed an approach to determining surveillance duration that attempts to balance risk of recurrence vs risk of non–renal cell carcinoma death after resection for renal cell carcinoma....
ECC 2015: Nivolumab Improves Overall Survival in Patients With Advanced Kidney Cancer
The targeted drug nivolumab (Opdivo) significantly prolonged survival in patients with advanced kidney cancer whose disease had progressed after their first treatment, according to the results (Abstract 3LBA) presented at the 2015 European Cancer Congress (ECC) in Vienna, Austria, and published...
ECC 2015: Cabozantinib Improves Survival in Patients With Advanced Kidney Cancer
Patients with advanced kidney cancer lived for nearly twice as long without their disease progressing if they were treated with cabozantinib (Cometriq), a drug that inhibits the action of tyrosine kinases. Toni Choueiri, MD, presented the research (Abstract 4LBA) at the Presidential Session of the...
Patient Characteristics in Trials of Targeted Therapies for Metastatic Renal Cell Carcinoma Differ From Those in Real-World Population
Patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in real-world clinical practice tend to be older and sicker than the patients enrolled in pivotal clinical trials of tyrosine kinase inhibitors. Conversely, patients with metastatic renal cell carcinoma treated...
Trebananib Plus Sunitinib Active in Metastatic Clear Cell Renal Cell Cancer
In a phase II study reported in the Journal of Clinical Oncology, Atkins et al found that combined treatment with the recombinant peptide-Fc fusion protein trebananib and the vascular endothelial growth factor (VEGF) inhibitor sunitinib (Sutent) was active in metastatic renal cell cancer and...
Omitting Doxorubicin From Postoperative Chemotherapy Has No Significant Survival Effect in Intermediate-Risk Wilms Tumor
In a phase III noninferiority trial (SIOP WT 2001) reported in The Lancet, Pritchard-Jones et al in the SIOP (International Society of Paediatric Oncology) Renal Tumours Study Group found that omission of doxorubicin from postoperative chemotherapy for stage II to III histologic intermediate-risk...
FDA Grants Breakthrough Therapy Designation to Lenvatinib for Metastatic Renal Cell Carcinoma
The U.S. Food and Drug Administration (FDA) granted lenvatinib (Lenvima) Breakthrough Therapy designation for investigational use in patients with advanced or metastatic renal cell carcinoma who were previously treated with a vascular endothelial growth factor (VEGF)-targeted therapy. Lenvatinib...
Phase II Trial Indicates No Benefit of Sorafenib, Temsirolimus, or Bevacizumab Doublets vs Bevacizumab Alone in Advanced Renal Cell Carcinoma
In a randomized phase II trial (BEST; ECOG-ACRIN E2804) reported in the Journal of Clinical Oncology, Flaherty et al found that adding the VEGFR inhibitor sorafenib (Nexavar) or the mTOR inhibitor temsirolimus (Torisel) to the VEGF inhibitor bevacizumab (Avastin) or using sorafenib-temsirolimus in...
Increased Use of Nephron-Sparing Surgery in Older Patients With Small Kidney Cancers
In a study reported in JAMA Surgery, Huang et al found that use of nephron-sparing surgery has more than doubled since 2001 among older patients with small kidney cancers. Use of nonsurgical approaches has remained stable. Study Details The study involved Surveillance, Epidemiology, and End...
16-Gene Assay Recurrence Score Predicts Recurrence After Surgery for Localized Renal Cell Carcinoma
In a study reported in The Lancet Oncology, Rini et al developed a 16-gene assay and recurrence score that predicted postsurgery outcome in patients with stage I to III clear cell renal cell carcinoma. Development Phase In the development phase, examination of the association between expression...
ASCO 2015: Study Clarifies Best Treatments for Non–Clear Cell Kidney Cancers
A head-to-head comparison of two biologic therapies used to treat a subset of patients with advanced kidney cancers provides much-needed clarity on the preferred method of first-line treatment. The phase II ASPEN trial, led by researchers at the Duke Cancer Institute, is the first and largest trial ...
ASCO 2015: Augmenting Standard Therapies Increases Cure Rates for High-Risk Wilms Tumor
Two phase III Children’s Oncology Group studies found that augmenting therapy with additional drugs improved outcomes for children with a high-risk form of Wilms tumor. These patients have a specific chromosomal abnormality associated with a poorer prognosis. In prior research, such patients...
Cancer Rates Significantly Increased Among Patients With Hepatitis C
Results presented on April 24 at The International Liver Congress 2015 (Abstract O058) in Vienna, Austria, show that cancer rates in patients with the hepatitis C virus (HCV) were significantly increased compared to the non-HCV cohort. The researchers suggest an extrahepatic manifestation of HCV...
Durable Responses With Nivolumab in Previously Treated Advanced Renal Cell Carcinoma
In a phase I cohort-expansion study reported in the Journal of Clinical Oncology, McDermott et al found that nivolumab (Opdivo) produced durable responses in patients with previously treated advanced renal cell carcinoma. Responses continued after nivolumab discontinuation in some patients. Study...
Study Finds Lycopene May Be Associated With Lower Risk for Kidney Cancer in Postmenopausal Women
A higher intake by postmenopausal women of lycopene, an antioxidant found in foods like tomatoes, watermelon, and papaya, may lower the risk of renal cell carcinoma, a type of kidney cancer. A study describing these findings was published by Ho et al in Cancer. In 2014, 63,920 estimated new cases...
Adjuvant Sorafenib and Sunitinib Do Not Improve Outcomes in Locally Advanced Kidney Cancer
Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant sorafenib (Nexavar) or sunitinib (Sutent). The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery ...
Nivolumab Shows Activity in Previously Treated Metastatic Renal Cell Carcinoma
In a randomized phase II trial reported in the Journal of Clinical Oncology, Motzer et al found that the PD-1 immune checkpoint inhibitor antibody nivolumab was associated with antitumor activity and manageable toxicity at three dose levels in patients with metastatic renal cell carcinoma who had...
Surveillance Guidelines Miss 30% of Renal Cell Carcinoma Recurrences After Nephrectomy
In a study reported in the Journal of Clinical Oncology, Stewart et al found that 30% or more of renal cell carcinoma recurrences were missed using National Comprehensive Cancer Network (NCCN) and American Urological Association (AUA) guidelines for surveillance after surgery for renal cell...
High-Dose Interleukin-2 Effective in Metastatic Renal Cell Cancer Pretreated With VEGF-Targeted Therapies
High-dose interleukin-2 can be effective in selected metastatic renal cell cancer patients pretreated with VEGF-targeted agents, according to research presented recently at the ESMO Symposium on Immuno-Oncology in Geneva (Abstract 4O). “Despite the wide and increasing range of therapies...
Patients With Advanced Papillary Kidney Cancer Respond Well to Bevacizumab/Erlotinib Combination Therapy
Researchers have found that patients with an advanced form of kidney cancer, for which there is no standard treatment and a very poor prognosis, respond well to a combination of two existing anticancer drugs. The combination of bevacizumab (Avastin) and erlotinib (Tarceva) produced excellent...
New Research Shows Association of Kidney Cancer With Use of Aristolochic Acid
New research by the international Cancer Genomics of the Kidney consortium (CAGEKID) reveals an important connection between kidney cancer and exposure to aristolochic acid, an ingredient in some herbal remedies. The findings, published by Scelo et al in Nature Communications, have important...
14 Million Major Medical Conditions Attributable to Cigarette Smoking
At least 14 million major medical conditions among U.S. adults aged 35 years and older were attributed to cigarette smoking by a study estimating the disease burden of cigarette smoking, which, according to the study’s authors, “remains immense.” Among current and former smokers,...
Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses Produce Similar Rates of Local Tumor Recurrence
Recurrence-free survival rates were similar for patients with cT1 renal masses who underwent partial nephrectomy or percutaneous cryoablation, according to the results of a retrospective trial reported by Thompson et al in European Urology. However, metastases-free survival was superior for...
Genomic Sequencing Reveals Unique Genetic Alterations in Chromophobe Renal Cell Carcinoma
An international scientific collaboration led by Baylor College of Medicine as part of The Cancer Genome Atlas initiative has revealed clues about genetic alterations that may contribute to a rare form of kidney cancer. The study, which describes the landscape of somatic genomic alterations of...
Phase II Trial Supports Use of First-Line Sunitinib vs Everolimus in Sequential Therapy in Metastatic Renal Cell Carcinoma
As reported by Motzer et al in the Journal of Clinical Oncology, the randomized phase II RECORD-3 trial showed that first-line use of everolimus did not achieve noninferiority in progression-free survival vs sunitinib (Sutent) in patients with metastatic renal cell carcinoma receiving sequential...
Metabolic Enzyme Stops Growth of Most Common Type of Kidney Cancer
In an analysis of metabolites in human kidney tissue, a research team from the Perelman School of Medicine at the University of Pennsylvania identified an enzyme key to applying the brakes on tumor growth. The new study, published in Nature by Simon et al, demonstrated that an enzyme called FBP1,...
Study Confirms Clinical Benefit for Interleukin-2 Immunotherapy in Patients With Advanced Kidney Cancer
A retrospective study published online ahead of print in Urology by researchers at Roswell Park Cancer Institute found that patients with metastatic kidney cancer—even those with chronic renal insufficiency—can tolerate and benefit from high-dose interleukin-2 (HDIL-2) immunotherapy....
Final Overall Survival Results Show No Difference for Pazopanib vs Sunitinib in First-Line Treatment of Clear Cell Metastatic Renal Cell Carcinoma
A phase III trial reported in 2013 showed noninferiority of pazopanib (Votrient) vs sunitinib (Sutent) for progression-free survival in first-line treatment of clear cell metastatic renal cell carcinoma. In a letter to the editor in The New England Journal of Medicine, Motzer et al provided the...
Crossover Trial Indicates Preference for Pazopanib Over Sunitinib in Patients With Metastatic Renal Cell Carcinoma
A crossover trial reported in the Journal of Clinical Oncology by Escudier et al found that patients with metastatic renal cell carcinoma preferred pazopanib (Votrient) vs sunitinib (Sutent) treatment. Study Details In the double-blind study, 168 patients with no prior systemic therapy for...
Antibody Could Be Used to Target Tumor-Enhancing Protein, Study Shows
In a phase I study published in PLOS ONE, treating patients with advanced melanoma and kidney cancer with an antibody that targets a tumor-enhancing protein was found to have an acceptable safety profile and showed preliminary evidence of antitumor activity. The findings by Morris et al shed light...
